This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
The genome rush of 1996 [Editorial]. Nature Biotechnology 14: 1516–1518.
Nebert, D.W. 1997. Polymorphisms in drug-metabolizing enzymes What is their clinical relevance and why do they exist? Am. J. Hum. Genet. 60: 265–271.
Idle J.R. and Smith R.L. 1979 Polymorphisms of oxidation at carbon centers of drugs and their clinical significance. Drug Metab. Rev. 9: 301–317.
Daly, A.K. 1995 Molecular basis of polymorphic drug metabolism. J. Mol. Med. 73: 539–553.
Ball, S. E., Scatina, J. A., Sisenwine, S. F., and Fisher, G. L. 1995 The application of in vitro models of drug metabolism and toxicity in drug discovery and drug development. Drug Chem. Tox. 18: 1–28.
Rendic, S. and Di Carlo, F. 1997 Human cytochromes P450 enzymes. A status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab. Rev. 29: 413–580. se
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ball, S., Borman, N. Pharmacogenetics and drug metabolism. Nat Biotechnol 15, 925–926 (1997). https://doi.org/10.1038/nbt1097-925
Issue Date:
DOI: https://doi.org/10.1038/nbt1097-925
This article is cited by
-
Challenges of implementing pharmacogenetics in the critical care environment
Nature Reviews Drug Discovery (2004)
-
Review of “angiotensin genotype, sodium reduction, weight loss, and prevention of hypertension: Trials of hypertension prevention, phase II”
Current Hypertension Reports (1999)